Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2

Executive Summary

Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.


Related Content

Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Chinese Stamp On Indian Pharma; All Eyes On Regulatory Flow
Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?
Dr. Reddy’s Warns Over Currency Effects As Emerging Markets Slide
Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs


Related Companies